LULU vs PFE: Which Is the Better Buy?
Side-by-side comparison of Lululemon Athletica Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Lululemon Athletica Inc. · Consumer Cyclical
$128.98
+307.7% upside to fair value
Grade C
VS
Pfizer Inc. · Healthcare
$26.33
+35.4% upside to fair value
Grade B
QuantHub Verdict
LULU has more upside to fair value
(+307.7%).
LULU trades at a lower forward P/E
(9.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LULU |
PFE |
| Current Price |
$128.98 |
$26.33 |
| Fair Value Estimate |
$525.85 |
$35.65 |
| Upside to Fair Value |
+307.7%
|
+35.4%
|
| Market Cap |
$15.1B |
$149.8B |
| Forward P/E |
9.7x
|
19.3x
|
| EV / EBITDA |
5.6x
|
12.9x
|
| Price / Sales |
1.4x
|
2.4x
|
| Price / FCF |
16.4x
|
16.5x
|
| Revenue Growth YoY |
+0.8%
|
-1.2%
|
| Gross Margin |
56.6%
|
70.3%
|
| Operating Margin |
19.8%
|
24.7%
|
| Return on Equity |
34.8%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
6.09%
|
6.06%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Lululemon Athletica Inc. is a premium athletic apparel retailer operating primarily in the consumer cyclical sector with a focus on apparel retail. The company has a strong brand and historically high profitability with a gross margin of 56.6% and ROE of 34.8%, but it faces significant near-term challenges including earnings pressure with a 21.6% decline in earnings in the most recent quarter and…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
LULU |
PFE |
| Zone Low |
$394.39 |
$26.74 |
| Zone High |
$446.97 |
$30.30 |
| In Buy Zone? |
Yes
|
Yes
|